Summary & Overview
CPT 0176U: IBSchek® Immunoassay for CdtB and Vinculin IgG Antibodies
CPT code 0176U is a Proprietary Laboratory Analyses (PLA) code for the IBSchek® immunoassay from Commonwealth Diagnostics International, which measures CdtB and vinculin IgG antibodies as biomarkers that may indicate irritable bowel syndrome (IBS). Nationally, PLA CPT codes like 0176U matter because they identify single-source, manufacturer- or lab-specific tests and are used in reporting and claims adjudication for novel diagnostic services.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical sites of service, and which major payers are included in the coverage discussion. The publication also outlines expected benchmarks for billing and coding behavior, summarizes relevant policy and reimbursement considerations affecting PLA tests, and provides clinical context for when this immunoassay is used in diagnostic workflows.
This summary is intended for billing managers, laboratory directors, and policy analysts seeking a national-level briefing on CPT code 0176U—what it represents, who covers it in major payer portfolios, and the types of operational and policy topics that follow in the full publication.
Billing Code Overview
CPT code 0176U is a Proprietary Laboratory Analyses (PLA) code assigned to the IBSchek® immunoassay produced by Commonwealth Diagnostics International. The test evaluates the presence of CdtB and vinculin IgG antibodies in a patient’s bloodstream to help identify biomarkers associated with irritable bowel syndrome (IBS).
Service type: Laboratory immunoassay diagnostic test
Typical site of service: Clinical laboratory or outpatient laboratory collection site
Clinical & Coding Specifications
Clinical Context
A 34-year-old patient presents to a gastroenterology clinic with a 2-year history of recurrent abdominal pain, bloating, and alternating constipation and diarrhea. Prior workup including stool studies, basic labs, celiac serology, and colonoscopy with biopsies were unrevealing for inflammatory bowel disease, celiac disease, or infection. The gastroenterologist considers post-infectious irritable bowel syndrome (IBS) as a working diagnosis and orders the proprietary immunoassay test IBSchek® to evaluate for serum IgG antibodies to cytolethal distending toxin B (CdtB) and vinculin.
The clinical workflow: the provider documents symptoms, prior negative evaluations, and orders test 0176U in the electronic medical record with appropriate specimen collection instructions. A peripheral blood specimen is drawn at the clinic or an outpatient lab collection site (typical site of service: outpatient clinic or independent laboratory). The specimen is sent to Commonwealth Diagnostics International for analysis. Results reporting includes qualitative/quantitative antibody levels and interpretive guidance indicating whether antibody patterns are consistent with IBS. The ordering provider reviews results, documents interpretation in the medical record, and integrates findings into the diagnostic formulation and management planning for the patient.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard reporting indicator | Use when no modifier applies and standard reporting is required |
11 | Professional component | Use when reporting the physician or practitioner’s interpretation component, if applicable and separable |
26 | Professional component | Use when billing only the professional component of a split service |
52 | Reduced services | Use if a reduced service was performed compared to the full test procedure |
53 | Discontinued service | Use when the specimen collection or test was started but discontinued for patient-related reasons |
59 | Data not available in the input. | Data not available in the input. |
62 | Two surgeons | Use rarely for procedures requiring co-surgeons; generally not applicable but included for surgical-team reporting when relevant |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure | Use if an unplanned return for a procedure is necessary; rarely applicable to laboratory testing |
80 | Assistant surgeon | Use when an assistant surgeon is involved; generally not applicable to laboratory testing |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207R00000X | Gastroenterology | Gastroenterologists commonly order IBSchek® when evaluating chronic functional bowel symptoms |
208D00000X | Family Medicine | Primary care clinicians frequently order initial evaluation and may order this laboratory test prior to referral |
207K00000X | Internal Medicine | Internists managing chronic GI complaints may order the test as part of diagnostic workup |
213E00000X | Clinical Pathology | Clinical pathologists or laboratory medicine specialists oversee test processing and result validation |
363L00000X | Diagnostic Laboratory | Laboratory services taxonomy for facilities performing specimen collection and shipment |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
K58.0 | Irritable bowel syndrome with diarrhea | Common IBS subtype evaluated with antibody testing for post-infectious etiology |
K58.1 | Irritable bowel syndrome with constipation | Common IBS subtype where immunoassay may be used in diagnostic workup |
K58.9 | Irritable bowel syndrome, unspecified | General diagnostic code used when IBS subtype not specified and IBSchek® may support diagnosis |
R10.9 | Abdominal pain, unspecified | Symptom prompting evaluation including IBS-focused testing |
R19.7 | Diarrhea, unspecified | Symptom that may lead the clinician to order IBSchek® when chronic and unexplained |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
81002 | Urinalysis, by dipstick or tablet reagent; non-automated, without microscopy | Often ordered in initial GI or abdominal pain workup to exclude urinary causes prior to targeted IBS testing |
83036 | Hemoglobin; glycosylated (A1C) | Ordered when evaluating systemic or metabolic contributors to symptoms, frequently part of general workup |
82784 | Ferroxidase (serum ferritin) | Ferritin testing is commonly performed to assess for iron deficiency contributing to fatigue or GI blood loss before attributing symptoms to IBS |
80053 | Comprehensive metabolic panel | Routinely ordered as part of baseline evaluation of patients with chronic GI complaints prior to specialized testing like 0176U |
81025 | Urine pregnancy test, by visual color comparison methods | Performed in women of childbearing potential as part of initial evaluation before imaging or other diagnostic steps |